Promising Vaccine Results for Preventing Cancers
- A vaccine developed by Nouscom, an immunotherapy company, may prevent cancer in people with lynch syndrome, according to results from a Phase Ib/II clinical trial.
- Lynch syndrome is a genetic condition caused by a mutation in one of four genes of the Mismatch Repair (MMR) system.
- Individuals with Lynch syndrome have a considerably increased risk of developing several cancers,including colorectal,endometrial,ovarian,and stomach cancers.
Vaccine Shows Promise in Preventing Cancer for Individuals with Lynch Syndrome
A vaccine developed by Nouscom, an immunotherapy company, may prevent cancer in people with lynch syndrome, according to results from a Phase Ib/II clinical trial. The study, conducted by researchers at the MD Anderson Cancer Center at the University of Texas, was published January 16, 2024, in Nature Medicine.
What is Lynch Syndrome?
Lynch syndrome is a genetic condition caused by a mutation in one of four genes of the Mismatch Repair (MMR) system. The MMR system is crucial for maintaining the integrity of genetic data during cell division, according to the National Cancer Institute.
Individuals with Lynch syndrome have a considerably increased risk of developing several cancers,including colorectal,endometrial,ovarian,and stomach cancers. The National Cancer Institute estimates that Lynch syndrome affects approximately 1 in 300 to 1 in 1,000 people.
The Nouscom vaccine targets cells with defects in the MMR system, prompting the immune system to recognize and destroy these possibly cancerous cells. The Phase Ib/II trial involved patients with Lynch syndrome who were at high risk of developing colorectal cancer.
while further research is needed, these initial findings represent a potential breakthrough in cancer prevention for individuals carrying the genetic predisposition of Lynch syndrome.
“it is essential for maintaining the integrity of the genetic information contained in the genome during the multiple cell divisions,” explains the National Cancer Institute regarding the function of the Mismatch Repair system.